BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 15 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 16 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 16 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 15 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 16 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 16 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
ADVERTISEMENT
Market News

Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year.  — Research and development expenses were $15.5 million versus $16.9 million for 2018.  — Cash and cash equivalents as of December 31, 2019, totaled […]

$ONTX March 25, 2020 1 min read
NYSE
$ONTX · Earnings

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year.  — Research and development expenses were $15.5 million versus $16.9 million for 2018.  — Cash and cash equivalents as of December 31, 2019, totaled […]

· March 25, 2020

— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net
loss of $1.49 per share, vs. $4.99 per share last year.

— Net loss was $21.5 million compared to $20.4 million last
year. 

— Research and development expenses were $15.5 million versus
$16.9 million for 2018. 

— Cash and cash equivalents as of December 31, 2019,
totaled $22.7 million, compared to $17 million as of December 31, 2018. 

ADVERTISEMENT